Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $20.40.

Several research firms have issued reports on AUPH. Oppenheimer dropped their price target on Aurinia Pharmaceuticals from $15.00 to $13.00 and set an "outperform" rating on the stock in a report on Monday, August 8th. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Monday, May 23rd. Royal Bank of Canada cut their target price on shares of Aurinia Pharmaceuticals from $22.00 to $18.00 and set an "outperform" rating for the company in a research report on Friday, August 5th. Finally, HC Wainwright cut their price objective on shares of Aurinia Pharmaceuticals from $30.00 to $26.00 and set a "buy" rating for the company in a research report on Tuesday, August 9th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Advisor Group Holdings Inc. increased its holdings in Aurinia Pharmaceuticals by 11.7% during the fourth quarter. Advisor Group Holdings Inc. now owns 19,986 shares of the biotechnology company's stock worth $455,000 after buying an additional 2,096 shares during the last quarter. Northern Trust Corp grew its holdings in Aurinia Pharmaceuticals by 4.8% in the 4th quarter. Northern Trust Corp now owns 101,476 shares of the biotechnology company's stock worth $2,321,000 after acquiring an additional 4,609 shares during the last quarter. Swiss National Bank lifted its position in shares of Aurinia Pharmaceuticals by 6.0% in the 4th quarter. Swiss National Bank now owns 240,200 shares of the biotechnology company's stock worth $5,493,000 after purchasing an additional 13,700 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth about $45,000. Finally, WINTON GROUP Ltd purchased a new position in Aurinia Pharmaceuticals during the 4th quarter valued at about $244,000. 35.20% of the stock is owned by institutional investors.

Aurinia Pharmaceuticals Trading Down 2.9 %

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last announced its earnings results on Thursday, August 4th. The biotechnology company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative return on equity of 38.01%. The business had revenue of $28.19 million for the quarter, compared to analyst estimates of $27.07 million. During the same quarter in the prior year, the business earned ($0.37) earnings per share. Sell-side analysts predict that Aurinia Pharmaceuticals will post -0.85 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

Read More

• Get a free copy of the StockNews.com research report on Aurinia Pharmaceuticals (AUPH)
• 3 High Margin Chipmakers Bound to Recover
• 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
• REV Group Has A Deep Moat In The World Of EVs
• Is G-III Apparel Group, Ltd. A Value Trap?
• Bank Of America Sees Upside In These 2 European Alcohol Stocks

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.